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Purpose: Early lung adenocarcinoma may present with ground-
glass opacity (GGO) component in computed tomography (CT)
scan. Epidermal growth factor receptor (EGFR) mutation had been
reported in patients with lung cancer with GGO patterns. Neverthe-
less, the correlation between clinical characteristics, CT image
patterns, and EGFR mutation status was indeterminate.
Methods: Patients with stage I lung adenocarcinoma with tumor
lesions less than 3 cm were included and classified into pure GGO,
part-solid, and solid patterns by CT scan images. All patients had
EGFR mutation test from frozen tumors. Available paraffin-embed-
ded archival tissues were microdissected into three different loca-
tions similar to CT images with central and peripheral parts of
tumor, and adjacent normal part for EGFR mutation tests.
Results: Totally, 162 patients were analyzed, 90 women and 72
men, and 128 nonsmokers. The patients included 35 (21.6%) pure
GGO, 41 (25.3%) part-solid, and 86 (53.1%) solid lesions. The
EGFR mutation rate was 64.2% (n  104). Analysis of the corre-
lation between CT image patterns and EGFR mutation, the less
GGO ratio had more typical mutation, especially L858R (p 
0.037). In 45 microdissected tumors, the central and peripheral parts
had the same EGFR mutation status. In adjacent normal parts, 5 of
32 (15.6%) EGFR mutant patients had identical mutation but none
in nonmutant patients.
Conclusions: In stage I lung adenocarcinoma, typical mutation,
especially L858R was detected more frequent in invasive solid
pattern and significantly less in pure GGO pattern. EGFR mutation
is an early event in the pathogenesis of lung adenocarcinoma and
may facilitate the tumor into aggressive behavior.
Key Words: Non-small cell lung cancer, Epidermal growth factor
receptor (EGFR), Ground-glass opacity.
(J Thorac Oncol. 2011;6: 1066–1072)
Non-small cell lung cancer (NSCLC) accounts for approx-imately 80% of lung cancers, and the frequency of
adenocarcinoma has increased recently.1 Surgery remains the
gold standard for stage I disease. Early detection is the main
way to cure NSCLC. Because of improvement of computed
tomography (CT) images with higher resolution and the
increasing prevalence of low-dose CT screening for lung
cancer detection, small and early NSCLCs are detected more
frequently than before.2,3 Small and early lung cancer lesions
may present in CT scan as ground-glass opacity (GGO),
part-solid, or solid patterns.4 GGO is also a very common CT
image pattern of NSCLC in Asian countries,2 including
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NSCLC is characterized by the accumulation of multi-
ple genetic alterations that results from the inactivation of
tumor suppressor genes, activation of oncogenes, and epige-
netic changes. Epidermal growth factor receptor (EGFR), a
transmembrane glycoprotein is involved in the cancer cell
proliferation, angiogenesis, and resistance to apoptosis.5,6
The EGFR is frequently overexpressed in NSCLC.7,8 Somatic
mutations in the EGFR gene have also been well documented
as a major determinant of the clinical response to small
molecule EGFR specific tyrosine kinase inhibitors, such as
gefitinib or erlotinib.9–11 The two most common EGFR mu-
tations, exon 19 deletion and L858R in exon 21, represent 85
to 90% of EGFR mutations.12 EGFR mutation had been
reported in patients with lung cancer with GGO patterns, and
these two typical EGFR mutations might determine the nat-
ural history of GGO lesions.13
In this study, we retrospectively surveyed the EGFR
mutation status of patients with stage I lung adenocarcinoma
(n  162) with including criteria as lung tumor lesion less
than 3 cm and adenocarcinoma (including bronchioloalveolar
cell carcinoma [BAC]). The association of image patterns on
CT scans and the EGFR mutation status in lung adenocarci-
noma will be determined.
PATIENTS AND METHODS
Patients
Part of the patients was from an ongoing Taiwan
national cooperative study—Genetic Epidemiologic Study of
Lung Adenocarcinoma—aimed at understanding the causes
of lung cancer, particularly lung adenocarcinoma, and the
other patients were from Taichung Veterans General Hospi-
tal. All the patients underwent surgical resection from Janu-
ary 2001 to March 2009. The lung tumor lesions were
completely resected with lymph node dissection. This study
was approved by the Joint Institutional Review Board of
Taiwan and the Institutional Review Board of Taichung
Veterans General Hospital. The pathological diagnoses were
based on the 2004 World Health Organization histologic
classification system.14 Tumor, node, and metastases staging
system was used according to the 6th edition of the American
Joint Committee for Cancer staging system.15 Clinical infor-
mation including patient’s age, gender, tumor location, tumor
size, stage, smoking status (nonsmoking defined as patients
had never smoked), the status of EGFR mutation, and CT
image patterns of the lung cancer was collected for analysis.
The excluding criteria were (1) nonadenocarcinoma
cell type, (2) pathological stages II, III, and IV, and (3) tumor
size large than 3 cm.
Image Patterns
The patients were divided into three groups such as
pure GGO, part-solid, and solid patterns according to the
images over the CT scanning. GGO was defined as a hazy
increase in lung attenuation without obscuring the underlying
bronchial or vascular structures. The tumor contents were
classified according to the extent occupied by GGO within
the whole tumor. Tumor shadow disappearance rate (TDR)
was used for presenting the GGO ratio.16 The clinicians
quantified the maximum dimension of the tumor (maxD) and
the largest dimension perpendicular to the maximum axis
(perD) on both lung and mediastinal windows. As previously
reported, TDR was defined as the following:
TDR  1  (maxD  perD on mediastinal windows/
maxD  perD on lung windows)
After modification from the study by Chung et al.,17 the
tumors were then classified into three patterns according to
the TDR. The first one was pure GGO pattern, which mean
there was no solid component in the tumor, and the TDR was
1 (Supplementary Figure S1A, http://links.lww.com/JTO/A83).
The second one was part-solid pattern, which mean only a few
solid component in the tumor, and the TDR was large than 0.5
(Supplementary Figure S1B, http://links.lww.com/JTO/A83).
The third one was the solid pattern, which means most of tumor
is solid content, and the TDR was less than 0.5.
DNA Extraction from Frozen Tumor Tissue for
EGFR Mutation Test
The frozen lung cancer tissues were obtained at surgery,
immediately snap frozen in liquid nitrogen, and stored until use.
Tumor specimens were procured for EGFR gene mutational
analysis with previous description.18 Briefly, DNA was ex-
tracted from the tumors using a QIAmp DNAMini kit (Qiagen,
Valencia, CA) following the manufacturer’s protocols. The
tyrosine kinase domain of the EGFR coding sequence, exons 18,
19, 20, and 21, was amplified by polymerase chain reaction and
sequenced bidirectionally with an ABI Prism 3730 DNA Ana-
lyzer following standard protocol.
DNA Extraction from Microdissected Paraffin-
Embedded Tissue for EGFR Mutation Test
Hematoxylin and eosin-stained sections of the available
archived pathology specimens were reviewed by the pathol-
ogists (Y.-C.Y. and T.-Y.C.). For tumors with part solid and
solid patterns, the central “solid” and peripheral “GGO” parts
of the tumor, and the adjacent nontumor lung tissue were
dissected under microscopy from paraffin-embedded tissues
for EGFR mutation test. For tumors with purely GGO pattern
radiologically, the central and peripheral parts of the tumor
were microdissected separately. Finally, the microdissected
specimens were obtained from three different locations (cen-
tral part of tumor, peripheral part of the tumor, and the
adjacent normal part) similar to the CT scan images.
Statistical Analysis
Categorical variables or continuous variables were an-
alyzed by 2 tests, except where a small size (5) required
the use of Fisher’s exact test or Student’s t test, respectively.
For multivariate analysis, multiple logistic regression with
stepwise selection method was carried out to select significant
variables. All reported p values were two sided, and a p value
less than 0.05 was considered as statistically significant. All
statistical analyses were performed using the SAS software
(version 13.0; SAS Inc., Chicago, IL).
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RESULTS
Patients, Clinical Features, and EGFR Mutation
Status
Totally, 162 patients were included in this study. Six of
them were BAC (6/162, 3.7%). All the six patients had pure
GGO patterns. The clinical factors and EGFR mutation status
are presented in Table 1. The median age was 59 years
(range: from 34 to 84 years). Female patients (n 90, 55.6%)
and nonsmokers (n  128, 79%) were predominant in this
study. Majority of tumor lesion (68%) was located at upper
lobes. Pure GGO pattern represented 21.6% (n  35), part-
solid pattern 25.3% (n  41), and solid pattern 53.1% (n 
86). The EGFR mutation rate was 64.2% (n  104), 42 cases
with exon 19 deletion (25.9%), 47 cases with L858R point
mutation (29.0%), and 15 cases (9.3%) were other types.
CT Image Patterns, Clinical Features, and EGFR
Mutation
According to the EGFR mutation status, female, non-
smoker had significantly more L858R point mutation com-
pared with wild type (p 0.017 and 0.035, respectively). The
exon 19 deletions were significantly present more in non-
smoker group (p  0.006) (Table 2).
The associations between clinical factors, EGFR muta-
tion status, and CT image patterns were presented in Table 3.
The results showed that age (p  0.006), tumor size (p 
0.0001), and EGFR mutation status (p  0.035) were signif-
icantly associated with CT image patterns. According to the
CT image patterns, patients older than 59 years had more
TABLE 1. Summary of Clinical Factors and EGFR Mutation
Status of the Patients
Variables N (n  162) (%)
Gender
Male 72 (44.4)
Female 90 (55.6)
Age, median (range) 59 (34–84)
Smoking status
Nonsmoker 128 (79.0)
Exsmoker 16 (9.9)
Current smoker 18 (11.1)
Primary tumor location
RUL 64 (39.5)
RML 11 (6.8)
RLL 25 (15.4)
LUL 46 (28.4)
LLL 16 (9.9)
Stage
IA 100 (61.7)
IB 62 (38.3)
EGFR mutation status
Wild type 58 (35.8)
L858R 47 (29.0)
Exon19 deletion 42 (25.9)
Others 15 (9.3)
Image patterns
Pure GGO pattern 35 (21.6)
Part-solid pattern 41 (25.3)
Solid pattern 86 (53.1)
EGFR, epidermal growth factor receptor; GGO, ground-glass opacity.
TABLE 2. Association between Clinical Factors and EGFR
Mutation Status with Wild Type, L858R, and Exon 19
Deletiona
Variables
Wild Type
(%)
(n  58)
L858R
(%)
(n  47)
Exon 19
Deletion (%)
(n  42) p1b p2c
Age (yr)d
59 30 (51.7) 16 (34.0) 20 (47.6) 0.069 0.685
59 28 (48.3) 31 (66.0) 22 (52.4)
Gender
Male 32 (55.2) 15 (31.9) 19 (45.2) 0.017 0.327
female 26 (44.8) 32 (68.1) 23 (54.8)
Smoking status
Nonsmoker 39 (67.2) 40 (85.1) 38 (90.5) 0.035 0.006
Exsmoker and
current
smoker
19 (32.8) 7 (14.9) 4 (9.5)
Tumor size
20 mm 33 (56.9) 24 (51.1) 22 (52.4) 0.551 0.654
20 mm 25 (43.1) 23 (48.9) 20 (47.6)
a p values were calculated by 2 test.
b p1 denotes the p values compared of wild type and L858R.
c p2 denotes the p values compared of wild type and exon 19 deletion.
d Age was divided to two groups according to median age.
EGFR, epidermal growth factor receptor.
TABLE 3. Association between Clinical Factors with EGFR
Mutation Status Added and CT Image Patterns
Variables
Pure GGO
(n  30),
N (%)
Part Solid
(n  37),
N (%)
Solid
(n  80),
N (%) p
Age (yr)
59 15 (50.0) 24 (64.9) 27 (33.8) 0.006
59 15 (50.0) 13 (35.1) 53 (66.2)
Gender
Male 10 (33.3) 19 (51.4) 37 (46.3) 0.316
female 20 (66.7) 18 (48.6) 43 (53.7)
Smoking status
Nonsmoker 25 (83.3) 29 (78.4) 63 (78.8) 0.849
Exsmoker and
current
smoker
5 (16.7) 8 (21.6) 17 (21.2)
Tumor size
20 mm 29 (96.7) 23 (62.2) 27 (33.8) 0.0001
20 mm 1 (3.3) 14 (37.8) 53 (66.2)
Mutation status
Wild type 18 (60.0) 12 (32.4) 28 (35.0) 0.035
Typical mutationc 12 (40.0) 25 (67.6) 52 (65.0)
a 2 test.
b The p values derived were between pure GGO versus part solid and solid patterns.
c Typical mutation denotes L858R and exon19 deletion.
EGFR, epidermal growth factor receptor; GGO, ground-glass opacity; CT, com-
puted tomography.
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solid pattern and less number of pure GGO or part-solid
pattern. In addition, the patients with tumor diameter large
than 2 cm and typical EGFR mutation had significantly less
number in pure GGO pattern than other types. The patients
with part-solid or solid pattern had more typical EGFR
mutation.
Further analysis was performed with trend test for the
proportion of EGFR mutation status among different image
patterns. Solid pattern had trend association with L858 point
mutation (p  0.024), but the trend association was not
obtained in the exon 19 deletion (p  0.272) although there
was a tendency (Table 4). To explore the interaction of CT
image patterns and EGFR mutation status in clinical covari-
ates including gender, smoking status, and tumor diameter,
the stratified analysis approach was performed. The signifi-
cant trend association was only obtained in female (p 
0.021), nonsmoker (p  0.011), and tumor diameter less than
2 cm (p  0.004) with L858R point mutation and solid
pattern tumor. Nevertheless, the association was not present
in the exon 19 deletion (Table 4).
In addition, the less GGO ratio significantly had more
L858R point mutation (p  0.037) (Figure 1A). If the tumor
size was also considered, pure GGO pattern had a trend to be
smaller size and had less EGFR mutation (Figure 1B).
The result of mutational pattern from the frozen non-
microdissected tissues was confirmed by 45 microdis-
sected tumor cells in formalin-fixed paraffin-embedded
tissues. The central and peripheral parts of tumor had the
same EGFR mutation status (Figure 2). One patient had
both exon 19 deletion and T790M mutation without any
previous treatment. EGFR mutations identical to the tu-
mors were detected in the adjacent normal part in 5 of 32
(15.6%) patients with EGFR mutant adenocarcinoma but
none in 13 patients without mutation in the tumors. In
these five patients with EGFR mutation in the adjacent
normal parts, there were three patients with L858R, one
with exon 19 deletion, and one with exon 18 mutation
(Supplementary Table S1, http://links.lww.com/JTO/A83).
DISCUSSION
The carcinogenesis of the development of lung adeno-
carcinoma is still unclear. Some authors propose that a
stepwise progression occurs from atypical adenomatous hy-
perplasia (AAH) through BAC to invasive adenocarci-
FIGURE 1. A, Ground-glass opacity
(GGO) ratio and epidermal growth
factor receptor (EGFR) mutation sta-
tus. B, Relationship of the GGO ra-
tio, tumor size, and EGFR mutation
status.
TABLE 4. Trend Test for the Proportion of EGFR Mutation
Status among Different Image Patterns
Variables
Wild
Type
(%)
L858R
(%)
Exon 19
Deletion
(%) p1a p2b
All patients
Image patterns n  58 n  47 n  42
Pure GGO 18 (31.0) 5 (10.6) 7 (16.7) 0.024 0.272
Part solid 12 (20.7) 12 (25.5) 13 (31.0)
Solid 28 (48.3) 30 (63.9) 22 (52.3)
Stratified by gender
Male n  32 n  15 n  19
Pure GGO 7 (21.9) 0 (0.0) 3 (15.8) 0.334 0.482
Part solid 8 (25.0) 7 (46.7) 4 (21.1)
Solid 17 (53.1) 8 (53.3) 12 (63.1)
Female n  26 n  32 n  23
Pure GGO 11 (42.3) 5 (15.6) 4 (17.4) 0.021 0.283
Part solid 4 (15.4) 5 (15.6) 9 (39.1)
Solid 11 (42.3) 22 (68.8) 10 (43.5)
Stratified by smoking
status
Nonsmoker n  39 n  40 n  38
Pure GGO 14 (35.9) 5 (12.5) 6 (15.8) 0.011 0.070
Part solid 9 (23.1) 9 (22.5) 11 (29.0)
Solid 16 (41.0) 26 (65.0) 21 (55.2)
Smoker n  19 n  7 n  4
Pure GGO 4 (21.1) 0 (0.0) 1 (25.0) 0.648 0.347
Part solid 3 (15.8) 3 (42.9) 2 (50.0)
Solid 12 (63.1) 4 (57.1) 1 (25.0)
Stratified by diameter
Diameter 20 mm n  33 n  24 n  22
Pure GGO 18 (54.6) 5 (20.8) 6 (27.3) 0.004 0.090
Part solid 8 (24.2) 6 (25.0) 9 (40.9)
Solid 7 (21.2) 13 (54.2) 7 (31.8)
Diameter 20 mm n  25 n  23 n  20
Pure GGO 0 (0.0) 0 (0.0) 1 (5.0) 0.390 0.317
Part solid 4 (16.0) 6 (26.1) 4 (20.0)
Solid 21 (84.0) 17 (73.9) 15 (75.0)
a p1 denotes the p values compared of wild type and L858R.
b p2 denotes the p values compared of wild type and deletion.
EGFR, epidermal growth factor receptor; GGO, ground-glass opacity.
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noma.19,20 Nevertheless, it is still unknown how the lesion
progresses over time in terms of radiological, pathological,
and molecular characteristics.
BAC or early adenocarcinoma has three image patterns
on CT scan included pure GGO, part solid, and solid.21,22
These three image patterns correspond roughly to a biological
range extending from benign lesions to invasive adenocarci-
noma. The ratio of solid components usually related to
disease progression.19 Investigators have reported that the
solid components in advanced-stage lesions are significantly
larger than those in lesions at earlier stage.19,23 Several
investigators have suggested that the CT image patterns of
small adenocarcinoma are closely related to the disease prog-
nosis and that these features might be more important prog-
nostic factors than are conventional considerations such as
tumor size.19,20,23,24 So lung cancer lesions with a solid
component within the GGO nodule suggest increasing bio-
logical virulence, which mean that a solid component in-
creases the level of suspicion for invasive adenocarcinoma.
EGFR mutations were detected in NSCLC and were
more often seen in lung adenocarcinoma, particularly among
Asians, females, and nonsmokers.25–27 The incidence of
EGFR mutation in lung adenocarcinoma in this study is very
similar to the study in Asian patients28 but higher than white
patients.29 The clinical implication of EGFR mutation is its
close relationship to the patient’s response to EGFR tyrosine
kinase inhibitors.9,10
The relationship of GGO and EGFR was ever studied.
Several studies have found a correlation between the EFGR
mutation and BAC or BAC-like growth patterns.30–33 Small
peripheral adenocarcinoma or BAC may present with a high
ratio of GGO components on CT scans. One would expect
that GGO patterns may predict the presence of EGFR muta-
tion, especially among female patients. In addition, L858R
was more common in small size of tumor.34 In the study of a
clinicopathologic correlation between AAH, BAC, and
EGFR mutation by Yoshida et al., EGFR mutations occur in
the early stage of lung adenocarcinoma, such as AAH and
BAC, suggesting that they might play an important role in
disease progression. EGFR mutations are less frequently
observed in AAH and BAC lesions compared with invasive
adenocarcinoma.35 Shigematsu et al.27 studied EGFR muta-
tion from seven pure BAC tumors out of 97 adenocarcino-
mas, and none of the seven tumors had EGFR TK domain
mutations. Even though there were no statistically significant
differences between EGFR TK domain mutation frequencies
and the presence or percentage of BAC features (p  0.29),
the mean percentage with BAC feature with EGFR TK
mutation was 30%, whereas it was 75% with negative EGFR
TK domain mutation. Both studies showed that BAC might
have less EGFR TK mutation than invasive adenocarcinoma.
In the study of correlation between EGFR mutation and
GGO patterns, Yoshida et al.13 found that EGFR mutations
had little association with the progressive behavior of pure
GGO. Glynn et al.36 surveyed the association of the imaging
characteristics with EGFR and KRAS mutations in patients
with lung adenocarcinoma with BAC features. The presence
of GGO on CT scan was not significantly associated with the
presence of an EGFR mutation (p  0.44). In five pure GGO
patients with a high percentage of BAC (75%), only one
(20%) was positive for an EGFR mutation. Chung et al.17 had
a research on pathologic and radiologic correlation between
EGFR mutation and multiple lung nodules with GGO pat-
terns. According to the CT appearances, EGFR mutation was
found in 38.4% of pure GGO lesions, 41.6% of mixed
lesions, and 50% of solid GGO lesions. From these three
researches, higher percentage of GGO had less EGFR TK
domain mutation. This is compatible with our result.
In our study, EGFR mutation was detected less fre-
quently in pure GGO lesions than in lesions with solid
component, especially L858R. The invasive adenocarcinoma,
such as tumors with part-solid and solid patterns, had higher
incidence of EGFR mutation. That is, EGFR mutation may
associate with the progression of tumor. In EGFR mutation
analyses using microdissection, the central and the peripheral
parts of tumor, and along with some of the adjacent nonneo-
plastic parts, always had the same EGFR mutation status. Our
data suggested that the less invasive or noninvasive tumor
parts presenting radiologically as peripheral GGO around
central solid pattern had the same EGFR mutation status with
the central invasive tumor part.
There are some possible explanations for the results.
First, EGFR mutation was acquired in the relatively late stage
in carcinogenesis of lung adenocarcinoma, and more invasive
adenocarcinoma had more EGFRmutation. Nevertheless, this
is against previous studies13,35 and also our data from the
microdissected tumors. Second, change in solid component
was characterized by a significant rise in the incidence of
allelic losses.37 Different allelic loss patterns were found
between the tumor cells in the central areas of alveolar
FIGURE 2. Computed tomography (CT) image and histo-
pathology of the tumor. A, CT scan with a part-solid pattern
lung adenocarcinoma over right lung and (B) the low-power
histopathology of the tumor in hematoxylin and eosin (H&E)
stain (20). There are invasive carcinoma cells in the central
part of tumor (C) and in situ carcinoma cells arranged in a
bronchioloalveolar pattern in the periphery (D). Both the
central and peripheral tumor parts have the same EGFR mu-
tation status, L858R.
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collapse or fibrosis and those in the peripheral region. The
tumor cells in the central fibrotic areas have progressed to a
more advanced stage than those in the peripheral regions.
Third, lung tumors with EGFR mutation may progress more
rapidly and develop into invasive cancer after combination
with other genetic changes than those without mutations
especially in central part of the tumor.
In our study, identical EGFR mutations in adjacent
normal epithelium in 5 of 32 (15.6%) patients with EGFR
mutant tumors suggest that the mutations occur as early
events in the pathogenesis of these lung adenocarcinomas,
starting from the histologically normal epitheliums. This
finding suggested field effect phenomenon in lung adenocar-
cinoma and was also reported by Tang et al.38 This finding
may lead to clinical applications to target early detection and
chemoprevention strategies. Nevertheless, even the central
part and peripheral part of the tumor lesions harbored the
same EGFR mutation status; the morphology patterns were
different with more invasive component in central part of the
tumors in part-solid and solid patterns. There must be in-
volved with other genetic changes. Recent studies revealed
that EGFR amplification commenced in the later stage of
invasive adenocarcinoma.39–43 Heterogeneous distribution of
the EGFR amplification within individual tumors, especially
the selective involvement in the invasive portions, supports
an association with the invasive phenotype. In our study,
part-solid and solid patterns had more EGFRmutation. EGFR
mutation may involve the progression of the tumors through
the combination of EGFR mutation and amplification and
probably contributes to the switching to a tumor with a
greater malignant potential. Other genes could also potentiate
EGFR mutation in lung adenocarcinoma, such as inactivation
of P53 may be associated with the appearance of central
consolidation.13
In our study, there were some differences between
L858R and exon 19 deletions. L858R mutation is more likely
to associate with female, and nonsmoker. Clinically, L858R
mutation and exon 19 deletions have different presentation.
Mitsudomi et al. found a correlation between EGFR genotype
and response rate. In that study, patients with an exon 19
deletion showed a higher clinical response than EGFR point
mutation. Nevertheless, it should be noted that the latter
group included all point mutations and not just the L858R
mutation.44 Rosell et al. reported that a better response was
associated with the exon 19 deletion than with the L858R
mutation (odds ratio, 3.08; p  0.001). In addition, the
presence of the L858R mutation and the diagnosis of bron-
chioloalveolar adenocarcinoma were associated with poor
prognosis compared with exon 19 deletion and adenocarci-
noma in multivariate analyses.29 Two reports compared the
differences in survivals between patients with exon 19 dele-
tions and with L858R mutations treated with gefitinib or
erlotinib.45,46 These data suggest that patients with an exon 19
deletions who are treated with gefitinib or erlotinib live
longer than those with a L858R mutation. Nevertheless, it is
possible that the mutation itself could have an effect on
outcome. In our study, if lung adenocarcinoma harbors EGFR
mutation, especially L858R, it may facilitate the tumor into
more aggressive behavior and resulted into solid pattern.
In summary, in stage I lung adenocarcinoma with
tumor size less than 3 cm, the part-solid and solid pattern
tumors had more typical EGFR mutation. L858R point mu-
tation was especially more frequent in invasive solid pattern.
Pure GGO pattern tends to with tumor size less than 2 cm and
has less typical EGFR mutation significantly, especially
L858R. By microdissection, EGFR mutation status is the
same in central and peripheral parts of the tumor, even in
some adjacent normal epitheliums. EGFR mutation occurs as
an early event in the pathogenesis of lung adenocarcinoma
and may facilitate the tumor into more aggressive behavior.
The difference between the typical EGFR mutations, L858R
and exon 19 deletion, and their involvement in the process of
lung adenocarcinoma formation needs further evaluation.
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